Adaptive Biotechnologies Corporation ( ADPT ) shares are trading flat. The stock gained premarket on possible continued momentum after the company announced preliminary fourth-quarter and fiscal-year revenues above estimates.

Unprecedented Growth: Revenue Soars 55% Year-Over-Year

Adaptive reported preliminary, unaudited revenue of approximately $72 million for the fourth quarter of 2025, representing a 51% increase compared to the same period in 2024. Full-year 2025 revenue totaled approximately $277 million, up 55% year over year.

The company said minimal residual disease revenue reached approximately $62 million in the fourth quarter and $212 million for the full year, reflecting growth of 54% and 46%, respectively, compared to 2024. Excluding MRD regulatory milestone revenue, full-year MRD revenue increased 45% year over year.

Adaptive also reported strong growth in clonoSEQ testing volume. Test volume increased 43% to approximately 30,000 tests in the fourth quarter of 2025 compared to the prior-year quarter. For the full year, approximately 105,600 clonoSEQ tests were delivered, representing a 39% increase from 2024.

As of Dec. 31, 2025, the company reported cash, cash equivalents, and marketable securities of approximately $227 million, excluding cash held by Digital Biotechnologies, Inc.

Adaptive Biotechnologies ( ADPT ) said it plans to release complete fourth-quarter and full-year 2025 financial results during its earnings call in February 2026.

Adaptive Shares Soar In Early Trading

ADPT Price Action: At the time of writing, Adaptive shares are down 0.11% at $18.24, according to data from Benzinga Pro,

This illustration was generated using artificial intelligence via Midjourney.